Literature DB >> 17201235

Effectiveness of instillation of triamcinolone acetonide into the middle ear for eosinophilic otitis media associated with bronchial asthma.

Yukiko Iino1, Hisayo Nagamine, Keiko Kakizaki, Takashi Komiya, Hiroaki Katano, Shoji Saruya, Kazuoki Kodera.   

Abstract

BACKGROUND: Eosinophilic otitis media (EOM) is a newly recognized middle ear disease found in asthmatic patients. EOM is characterized by a highly viscous middle ear effusion that contains many eosinophils and is extremely unresponsive to conventional treatments for common otitis media. To our knowledge, no systemic study regarding the efficacy of treatments for EOM has been performed.
OBJECTIVE: To determine the effectiveness of instillation of triamcinolone acetonide, which is a suspension of steroids, into the mesotympanum and eustachian tube as a treatment for patients with EOM.
METHODS: We studied the efficacy of the instillation of triamcinolone acetonide in 43 ears of 24 patients with EOM. Efficacy was evaluated according to the length of the period without middle ear effusion or otorrhea. We also determined the otomicroscopic findings and the hearing levels before and after therapy. For controls, 27 ears of 14 patients treated by topical administration of betamethasone were similarly evaluated.
RESULTS: The middle ear effusion or otorrhea was controlled for more than 3 weeks after 1 instillation of triamcinolone acetonide in 35 ears, and the efficacy rate (81%) was significantly higher than that in the controls (7 ears, 26%). In the triamcinolone acetonide group, the average air conduction hearing level at the speech frequency range was significantly improved, and deterioration of the bone conduction hearing threshold was rarely found during therapy.
CONCLUSION: The instillation of triamcinolone acetonide into the mesotympanum and eustachian tube is an effective treatment for patients with EOM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17201235     DOI: 10.1016/S1081-1206(10)60967-2

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  9 in total

Review 1.  Is there an association between otitis media and nasal polyposis?

Authors:  Cécile Parietti-Winkler; Roger Jankowski
Journal:  Curr Allergy Asthma Rep       Date:  2011-12       Impact factor: 4.806

Review 2.  Eosinophilic Otitis Media: the Aftermath of Eosinophil Extracellular Trap Cell Death.

Authors:  Shigeharu Ueki; Nobuo Ohta; Masahide Takeda; Yasunori Konno; Makoto Hirokawa
Journal:  Curr Allergy Asthma Rep       Date:  2017-05       Impact factor: 4.806

3.  Eosinophilic Otitis Media: Modern Aspects of Pathogenesis, Clinical Features, Diagnosis and Treatment.

Authors:  Elena Shevchik; Valery Svistushkin; Galina Nikiforova; Anna Zolotova
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2020-06-18

4.  Cytokine profile of nasal and middle ear polyps in a patient with Woakes' syndrome and eosinophilic otitis media.

Authors:  Marie De Loof; Els De Leenheer; Gabriële Holtappels; Claus Bachert
Journal:  BMJ Case Rep       Date:  2016-05-03

Review 5.  Eosinophilic otitis media: a new middle ear disease entity.

Authors:  Yukiko Iino
Journal:  Curr Allergy Asthma Rep       Date:  2008-11       Impact factor: 4.806

6.  An experimental study of inner ear injury in an animal model of eosinophilic otitis media.

Authors:  Atsushi Matsubara; Hisanori Nishizawa; Akira Kurose; Takashi Nakagawa; Junko Takahata; Akira Sasaki
Journal:  Acta Otolaryngol       Date:  2013-12-23       Impact factor: 1.494

7.  Optimal control of asthma improved eosinophilic otitis media.

Authors:  Yukako Seo; Manabu Nonaka; Yukie Yamamura; Ruby Pawankar; Etsuko Tagaya
Journal:  Asia Pac Allergy       Date:  2018-01-24

8.  Role of Interleukin 5 Inhibition in the Treatment of Eosinophilic Otitis Media.

Authors:  Nathaniel K Breslin; N Hadley Heindel; Rex S Haberman
Journal:  OTO Open       Date:  2021-02-02

9.  Improvement of eosinophilic otitis media by optimized asthma treatment.

Authors:  Yukako Tanaka; Manabu Nonaka; Yukie Yamamura; Etsuko Tagaya; Ruby Pawankar; Toshio Yoshihara
Journal:  Allergy Asthma Immunol Res       Date:  2013-04-01       Impact factor: 5.764

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.